PSA provocation by bipolar androgen therapy may predict duration of response to first‐line androgen deprivation: Updated results from the BATMAN study-Reference-Cited by-同舟云学术

PSA provocation by bipolar androgen therapy may predict duration of response to first‐line androgen deprivation: Updated results from the BATMAN study

Published:2022-08-08 Issue:16 Volume:82 Page:1529-1536
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Denmeade Samuel¹^ORCID,Lim Su J.¹,Isaaccson Velho Pedro¹²,Wang Hao¹^ORCID

Affiliation:

1. The Johns Hopkins Kimmel Comprehensive Cancer Center Baltimore Maryland USA

2. Hospital Moinhos de Vento Porto Alegre Brazil

Funder

National Cancer Institute

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24426

Reference14 articles.

1. Studies on prostatic cancer

2. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study

3. Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer

4. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study

5. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synchronous metastatic prostate cancer and male breast cancer while on testosterone replacement therapy: Case report;International Journal of Surgery Case Reports;2024-09

2. Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire;Biomedicines;2023-07-24

3. First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer;The Prostate;2023-05-27

4. Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review;Frontiers in Endocrinology;2023-04-11